Search results
Results from the WOW.Com Content Network
The WHO Model List of Essential Medicines (aka Essential Medicines List or EML[ 1 ]), published by the World Health Organization (WHO), contains the medications considered to be most effective and safe to meet the most important needs in a health system. [ 2 ] The list is frequently used by countries to help develop their own local lists of ...
Essential medicines. Essential medicines, as defined by the World Health Organization (WHO), are the medicines that "satisfy the priority health care needs of the population". [1] Essential medicines are the medications that people should have access to at all times in sufficient amounts. These medications should be generally affordable. [2]
Human Factors Integration (HFI) is the process adopted by a number of key industries (notably defence and hazardous industries like oil & gas) in Europe to integrate human factors and ergonomics into the systems engineering process. Although each industry has a slightly different domain, the underlying approach is the same.
Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. [1] They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS. [1][2] In these situations they decrease the need for blood transfusions. [2]
Alternative medicine is any practice that aims to achieve the healing effects of medicine despite lacking biological plausibility, testability, repeatability or evidence of effectiveness. Unlike modern medicine, which employs the scientific method to test plausible therapies by way of responsible and ethical clinical trials, producing ...
Adalimumab was approved for medical use in the United States in 2002. [44] [47] It is on the World Health Organization's List of Essential Medicines. [48] It is available as a biosimilar medication. [49] In 2021, it was the 236th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [50] [51]
t. e. The United States Food and Drug Administration 's Investigational New Drug (IND) program is the means by which a pharmaceutical company obtains permission to start human clinical trials and to ship an experimental drug across state lines (usually to clinical investigators) before a marketing application for the drug has been approved.
In the 1980s, the European Union began harmonising regulatory requirements. In 1989, Europe, Japan, and the United States began creating plans for harmonisation. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) was created in April 1990 at a meeting in Brussels.